Literature DB >> 21059838

Modelling the interactions between herpes simplex virus type 2 and HIV: implications for the HIV epidemic in southern India.

Anna M Foss1, Peter T Vickerman, Philippe Mayaud, Helen A Weiss, B M Ramesh, Sushena Reza-Paul, Reynold Washington, James Blanchard, Stephen Moses, Catherine M Lowndes, Michel Alary, Charlotte H Watts.   

Abstract

BACKGROUND: The role of herpes simplex virus type 2 (HSV-2) in the HIV epidemic and the potential impact of HSV-2 suppressive therapy have previously been explored only within the context of sub-Saharan Africa. In this analysis, modelling is used to estimate the contribution of HSV-2 to HIV transmission from clients to female sex workers (FSW) in a southern Indian setting and the maximum potential impact of 'perfect' HSV-2 suppressive therapy on HIV incidence.
METHODS: A dynamic HSV-2/HIV model was developed, parameterised and fitted to Mysore data. The model estimated the attributable fractions of HIV infections due to HSV-2. Multivariate sensitivity analyses and regression analyses were conducted.
RESULTS: The model suggests that 36% (95% CI 22% to 62%) of FSW HIV infections were due to HSV-2, mostly through HSV-2 asymptomatic shedding. Even if HSV-2 suppressive therapy could eliminate the effect of HSV-2 on HIV infectivity among all co-infected clients, only 15% (95% CI 3% to 41%) of HIV infections among FSW would have been averted. 36% (95% CI 18% to 61%) of HIV infections among HSV-2-infected FSW could have been averted if suppressive therapy reduced their risk of HIV acquisition to that of HSV-2-uninfected FSW.
CONCLUSIONS: HSV-2 contributes substantially to HIV in this southern Indian context. However, even in the best case scenario, HSV-2 suppressive therapy is unlikely to reduce HIV transmission or acquisition by more than 50% (as aimed for in recent trials), because of the limited strength of the interaction effect between HSV-2 and HIV.

Entities:  

Mesh:

Year:  2010        PMID: 21059838      PMCID: PMC3920054          DOI: 10.1136/sti.2009.041699

Source DB:  PubMed          Journal:  Sex Transm Infect        ISSN: 1368-4973            Impact factor:   3.519


  42 in total

Review 1.  Herpes simplex virus and HIV-1: deciphering viral synergy.

Authors:  Philippe Van de Perre; Michel Segondy; Vincent Foulongne; Abdoulaye Ouedraogo; Issouf Konate; Jean-Marie Huraux; Philippe Mayaud; Nicolas Nagot
Journal:  Lancet Infect Dis       Date:  2008-08       Impact factor: 25.071

2.  Interactions between herpes simplex virus type 2 and human immunodeficiency virus type 1 infection in African women: opportunities for intervention.

Authors:  F X Mbopi-Kéou; G Grésenguet; P Mayaud; H A Weiss; R Gopal; M Matta; J L Paul; D W Brown; R J Hayes; D C Mabey; L Bélec
Journal:  J Infect Dis       Date:  2000-09-08       Impact factor: 5.226

3.  Negative mucosal synergy between Herpes simplex type 2 and HIV in the female genital tract.

Authors:  Anuradha Rebbapragada; Charles Wachihi; Christopher Pettengell; Sherzana Sunderji; Sanja Huibner; Walter Jaoko; Blake Ball; Keith Fowke; Tony Mazzulli; Francis A Plummer; Rupert Kaul
Journal:  AIDS       Date:  2007-03-12       Impact factor: 4.177

Review 4.  Herpes simplex virus type 2: epidemiology and management options in developing countries.

Authors:  G Paz-Bailey; M Ramaswamy; S J Hawkes; A M Geretti
Journal:  Sex Transm Infect       Date:  2006-11-10       Impact factor: 3.519

5.  Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial.

Authors:  Connie Celum; Anna Wald; James Hughes; Jorge Sanchez; Stewart Reid; Sinead Delany-Moretlwe; Frances Cowan; Martin Casapia; Abner Ortiz; Jonathan Fuchs; Susan Buchbinder; Beryl Koblin; Sheryl Zwerski; Scott Rose; Jing Wang; Lawrence Corey
Journal:  Lancet       Date:  2008-06-21       Impact factor: 79.321

6.  Herpes simplex virus (HSV)-suppressive therapy decreases plasma and genital HIV-1 levels in HSV-2/HIV-1 coinfected women: a randomized, placebo-controlled, cross-over trial.

Authors:  Jared M Baeten; Lara B Strick; Aldo Lucchetti; William L H Whittington; Jorge Sanchez; Robert W Coombs; Amalia Magaret; Anna Wald; Lawrence Corey; Connie Celum
Journal:  J Infect Dis       Date:  2008-12-15       Impact factor: 5.226

7.  Increased genital shedding of herpes simplex virus type 2 in HIV-seropositive women.

Authors:  M Augenbraun; J Feldman; K Chirgwin; J Zenilman; L Clarke; J DeHovitz; S Landesman; H Minkoff
Journal:  Ann Intern Med       Date:  1995-12-01       Impact factor: 25.391

Review 8.  Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies.

Authors:  Esther E Freeman; Helen A Weiss; Judith R Glynn; Pamela L Cross; James A Whitworth; Richard J Hayes
Journal:  AIDS       Date:  2006-01-02       Impact factor: 4.177

9.  Virus-specific CD8+ T cells accumulate near sensory nerve endings in genital skin during subclinical HSV-2 reactivation.

Authors:  Jia Zhu; David M Koelle; Jianhong Cao; Julio Vazquez; Meei Li Huang; Florian Hladik; Anna Wald; Lawrence Corey
Journal:  J Exp Med       Date:  2007-02-26       Impact factor: 14.307

10.  Population-level effect of potential HSV2 prophylactic vaccines on HIV incidence in sub-Saharan Africa.

Authors:  Esther E Freeman; Richard G White; Roel Bakker; Kate K Orroth; Helen A Weiss; Anne Buvé; Richard J Hayes; Judith R Glynn
Journal:  Vaccine       Date:  2008-12-09       Impact factor: 3.641

View more
  4 in total

1.  Cost-effectiveness of tenofovir gel in urban South Africa: model projections of HIV impact and threshold product prices.

Authors:  Fern Terris-Prestholt; Anna M Foss; Andrew P Cox; Lori Heise; Gesine Meyer-Rath; Sinead Delany-Moretlwe; Thomas Mertenskoetter; Helen Rees; Peter Vickerman; Charlotte H Watts
Journal:  BMC Infect Dis       Date:  2014-01-09       Impact factor: 3.090

Review 2.  Review of mathematical models of HSV-2 vaccination: Implications for vaccine development.

Authors:  Ian H Spicknall; Katharine J Looker; Sami L Gottlieb; Harrell W Chesson; Joshua T Schiffer; Jocelyn Elmes; Marie-Claude Boily
Journal:  Vaccine       Date:  2018-04-04       Impact factor: 3.641

3.  What Is the Burden of Heterosexually Acquired HIV Due to HSV-2? Global and Regional Model-Based Estimates of the Proportion and Number of HIV Infections Attributable to HSV-2 Infection.

Authors:  Romain Silhol; Helen Coupland; Rebecca F Baggaley; Lori Miller; Lisa Staadegaard; Sami L Gottlieb; James Stannah; Katherine M E Turner; Peter Vickerman; Richard Hayes; Philippe Mayaud; Katharine J Looker; Marie-Claude Boily
Journal:  J Acquir Immune Defic Syndr       Date:  2021-09-01       Impact factor: 3.771

4.  Modelling the impact of chlamydia screening on the transmission of HIV among men who have sex with men.

Authors:  Maria Xiridou; Henrike J Vriend; Anna K Lugner; Jacco Wallinga; Johannes S Fennema; Jan M Prins; Suzanne E Geerlings; Bart J A Rijnders; Maria Prins; Henry J C de Vries; Maarten J Postma; Maaike G van Veen; Maarten F Schim van der Loeff; Marianne A B van der Sande
Journal:  BMC Infect Dis       Date:  2013-09-18       Impact factor: 3.090

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.